Scaling AAV5 production from bench to industrial scale: strategies for efficient, de-risked manufacturing

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Scaling AAV5 production from bench to industrial scale: strategies for efficient, de-risked manufacturing

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

This webinar presents comparative production data across three fixed-bed scales (2.65 m², 33 m², and 333 m²) and outlines a complete scaling strategy from bench-top to large-scale manufacturing for AAV5 production in adherent cells. You’ll see detailed results on metabolites, viral titer, and empty/full capsid ratios, and learn how to translate these findings into a reliable and scalable upstream process.

The session will explore how triple transfection of adherent HEK293 cells can be applied effectively across scales, and how fixed-bed bioreactor systems enable automated, risk-reduced industrialization of adherent cell manufacturing. Attendees will also gain practical guidance on moving from R&D to GMP faster – while maintaining control over cost, dose, and speed.

Explore strategies for overcoming common bottlenecks of 2D flatware systems, illustrating how single-use fixed-bed bioreactors can simplify process transfer, reduce variability, and support large-scale viral vector production. Key considerations for choosing the right upstream approach when scaling viral vector processes will also be highlighted, focusing on balancing performance, cost efficiency, and manufacturing agility.

Attend to learn about:

Quantitative production data from three fixed-bed scales, including metabolite trends, titers, and empty/full capsid ratios
See how bench-top results correlate with large-scale outcomes, providing a roadmap for scaling AAV5 manufacturing
Understand how automated fixed-bed systems reduce process variability and improve yield consistency during industrialization

Anne MacIntyre

Senior Scientist, Viral Vector R&D Upstream at Cytiva

Anne MacIntyre is a Senior Scientist for Cytiva R&D in Westborough, MA, USA supporting the advancement and implementation of cutting-edge products and processes for advanced therapy medicinal products. Having accumulated 20 years of industry insight into upstream process development across both adherent and suspension cell culture platforms, Anne now concentrates on gene therapy viral vector applications and technical support, including the iCELLis™ fixed-bed bioreactor. Her extensive experience has enabled her to provide effective solutions to a wide range of bioprocessing challenges.

Sara Krekels

Senior Upstream Field Application Specialist at Cytiva

As field application specialist, Sara Krekels supports biomanufacturing companies across Europe in their implementation, optimization and scale-up of single-use bioreactor processes. With nine years of experience on the iCELLis™ fixed bed bioreactor platform and a strong foundation from previous quality and product engineering roles, she bridges technical insight with practical application to accelerate biomanufacturing success.

You have registered for this webinar